NVCR - NovoCure Limited - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

1.42B

Cash

940.8M

Avg Qtr Burn

-5.188M

Short % of Float

7.94%

Insider Ownership

1.22%

Institutional Own.

85.56%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Gemcitabine & Nab-paclitaxel w/ NovoTTF-200T Details Pancreatic cancer	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Stereotactic radiosurgery (SRS) w/ NovoTTF-200M Details Non-small cell lung carcinoma, Brain metastases Big Mover™ Suspected Mover™ Susp. Mover™	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Immune checkpoint inhibitors or docetaxel w/ NovoTTF-200T Details Non-small cell lung carcinoma	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Paclitaxel w/ NovoTTF-100L(O) Details Ovarian cancer	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.